Table 1 Baseline characteristics in patients with advanced hepatobiliary cancers (n = 80)
Variables | Values | Total (n) | Percent (%) |
|---|---|---|---|
Clinicopathological factors | |||
 Age (years) | < 65 / ≥65 | 50/30 | 62.5/37.5 |
 Gender | Female / Male | 27/53 | 33.8/66.3 |
 ECOG-PS | 0 / 1 / 2 | 14/52/14 | 17.5/65.0/17.5 |
 BMI (kg/m2) | < 23 / ≥23 | 44/36 | 55.0/45.0 |
 Tumor Type | HCC / BTC / cHCC-CC | 33/44/3 | 41.3/55.0/3.8 |
 Previous anticancer therapy | No / Yes | 25/55 | 31.3/68.8 |
 Prior surgery | No / Yes | 44/36 | 55.0/45.0 |
 Prior chemotherapy | No / 1st line / 2nd line / ≥3rd line | 47/17/7/9 | 58.8/21.3/8.8/11/3 |
 Prior radiotherapy | No / Yes | 66/14 | 82.5/17.5 |
 Prior TACE | No / 1 / 2 / ≥3 | 60/3/5/12 | 75.0/3.8/6.3/15.0 |
 Prior RFA | No / Yes | 71/9 | 88.8/11.3 |
Laboratory factors | |||
 Ferritin (ng/mL) | Lowa / Highb | 45/35 | 56.3/43.8 |
 Hb (g/dL) | Lowc / Highd | 50/30 | 62.5/37.5 |
 Total bilirubin (mg/dL) | ≤1.2 / > 1.2 | 64/16 | 80.0/20.0 |
 AST (IU/L) | < 40 / ≥40 | 37/43 | 46.3/53.8 |
 ALT (IU/L) | < 40 / ≥40 | 46/34 | 57.5/42.5 |
 γ-GT (IU/L) | ≤66 / > 66 | 25/55 | 31.3/68.8 |
 PT INR | ≤1.16 / > 1.16 | 57/23 | 71.3/28.8 |
 Albumin (g/dL) | < 3.5 / ≥3.5 | 13/67 | 16.3/83.8 |
 WBC (×103/μL) | < 10.0 / ≥10.0 | 70/10 | 87.5/12.5 |
 CRP (mg/L) | < 10.0 / ≥10.0 | 40/40 | 50.0/50.0 |